CL2017000118A1 - Métodos y composiciones para tratar desórdenes relacionados con el vih - Google Patents

Métodos y composiciones para tratar desórdenes relacionados con el vih

Info

Publication number
CL2017000118A1
CL2017000118A1 CL2017000118A CL2017000118A CL2017000118A1 CL 2017000118 A1 CL2017000118 A1 CL 2017000118A1 CL 2017000118 A CL2017000118 A CL 2017000118A CL 2017000118 A CL2017000118 A CL 2017000118A CL 2017000118 A1 CL2017000118 A1 CL 2017000118A1
Authority
CL
Chile
Prior art keywords
compositions
methods
related disorders
treating hiv
hiv
Prior art date
Application number
CL2017000118A
Other languages
English (en)
Inventor
Celia Dominguez
Ignacio Muñoz-Sanjuan
Leticia Toledo-Sherman
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55079070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000118(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of CL2017000118A1 publication Critical patent/CL2017000118A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>METODO PARA EL TRATAMIENTO DEL TRASTORNO RELACIONADO CON VIH EN UN SUJETO CON VIH QUE COMPRENDE LA ADMINISTRACIÓN COMPLEMENTARIA DE UN COMPUESTO DERIVADO DEL ÁCIDO 6-(FENIL)PIRIMIDIN-4-CARBOXÍLICO; Y COMPOSICIÓN QUE COMPRENDE UN AGENTE ANTIVIRAL Y DICHO COMPUESTO.</p>
CL2017000118A 2014-07-17 2017-01-17 Métodos y composiciones para tratar desórdenes relacionados con el vih CL2017000118A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462025840P 2014-07-17 2014-07-17

Publications (1)

Publication Number Publication Date
CL2017000118A1 true CL2017000118A1 (es) 2017-10-20

Family

ID=55079070

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000118A CL2017000118A1 (es) 2014-07-17 2017-01-17 Métodos y composiciones para tratar desórdenes relacionados con el vih

Country Status (23)

Country Link
US (1) US10258621B2 (es)
EP (1) EP3169684B1 (es)
JP (1) JP2017520610A (es)
KR (1) KR20170026633A (es)
CN (2) CN114588157A (es)
AP (1) AP2017009724A0 (es)
AU (1) AU2015289492B2 (es)
BR (1) BR112017000922A2 (es)
CA (1) CA2955379C (es)
CL (1) CL2017000118A1 (es)
CO (1) CO2017001447A2 (es)
CR (1) CR20170061A (es)
EA (1) EA034528B1 (es)
EC (1) ECSP17010817A (es)
ES (1) ES2747633T3 (es)
IL (1) IL250114B (es)
MX (1) MX372995B (es)
PE (1) PE20170770A1 (es)
PH (1) PH12017500110A1 (es)
SG (1) SG11201700341PA (es)
SV (1) SV2017005357A (es)
UA (1) UA120856C2 (es)
WO (1) WO2016011316A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
WO2018039521A1 (en) * 2016-08-26 2018-03-01 Concert Pharmaceuticals, Inc. Deuterated cenicriviroc
US20220160710A1 (en) * 2019-03-08 2022-05-26 University Of Virginia Patent Foundation Compositions and methods for treating or preventing alzheimer's disease
WO2023010061A1 (en) * 2021-07-27 2023-02-02 University Of Miami Nanoparticles and uses thereof for treatment of human immunodeficiency virus
CN114601832A (zh) * 2021-12-01 2022-06-10 南方医科大学 犬尿喹啉酸在制备改善hiv-1相关神经认知功能障碍药物中的应用

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3908012A (en) 1970-10-05 1975-09-23 Pfizer Arylpyrimidines-inhibitors of platelet aggregation and bronchodilators
US3707560A (en) 1970-10-05 1972-12-26 Pfizer Certain 4-amino-6-aryl-pyrimidines
FR2204406A1 (en) 1972-10-26 1974-05-24 Delalande Sa 1-Phenyl-3-aminocarbonylpropan-1-one oxime carbamates - with analgesic, antiinflammatory, hypotensive and sedative activities etc.
US3950525A (en) 1973-06-19 1976-04-13 Pfizer Inc. Relaxation of smooth muscle in a mammal
US3935202A (en) 1974-03-18 1976-01-27 American Home Products Corporation 3-(4-biphenylylcarbonyl)propionamido cephalosporin derivatives
US4634689A (en) 1985-10-31 1987-01-06 Schering Corporation Phosphinylalkanoyl imino acids
DE3609596A1 (de) 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
JPH0788357B2 (ja) 1986-10-27 1995-09-27 吉富製薬株式会社 ピペラジン化合物
ZW21687A1 (en) 1986-12-12 1988-07-20 Hoffmann La Roche Triazine derivatives
JPH01113377A (ja) 1987-10-23 1989-05-02 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
MX16687A (es) 1988-07-07 1994-01-31 Ciba Geigy Ag Compuestos de biarilo y procedimiento para su preparacion.
US5102904A (en) 1989-12-08 1992-04-07 American Cyanamid Company N-oxygenated arylpyrrole insecticidal, acaricidal and nematicidal agents and use thereas
AU644159B2 (en) 1990-05-17 1993-12-02 Novartis Ag 2-anilino-4-cyanopyrimidine derivatives
DE4103695A1 (de) 1991-02-07 1992-08-13 Basf Ag Oximether und diese enthaltende fungizide
WO1995023135A1 (en) 1991-03-07 1995-08-31 Fisons Corporation Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
JPH0741459A (ja) 1993-07-29 1995-02-10 Sumitomo Pharmaceut Co Ltd 新規エラスターゼ阻害剤
PT656348E (pt) 1993-12-03 2000-10-31 Hoffmann La Roche Derivados do acido acetico como medicamentos
US5338739A (en) 1994-03-10 1994-08-16 Hoechst-Roussel Pharmaceuticals Inc. (Pyrrolidinyl)phenyl carbamates, compositions and use
DE4430639A1 (de) 1994-08-29 1996-03-07 Bayer Ag Verwendung von 5-substituierten Pyridin- und Hexahydrochinolin-3-carbonsäurederivaten
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
CN1205194C (zh) 1995-11-17 2005-06-08 拜尔公司 联苯醚－噁唑啉类化合物及其作为害虫防治剂的应用
NZ323329A (en) 1995-12-22 1999-02-25 Warner Lambert Co 4-phenyl-piperidin-1-yl butyric acid derivatives and medicaments
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
AU4159197A (en) 1996-09-04 1998-03-26 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
KR20000057444A (ko) 1996-12-09 2000-09-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 심기능부전 및 심실확장의 치료 및 예방 방법
ES2212142T3 (es) 1996-12-17 2004-07-16 Warner-Lambert Company Llc Uso de inhibidores de metaloproteinasas de la matriz para promover la curacion de heridas.
AU6279598A (en) 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists
GB2338957B (en) 1997-02-19 2001-08-01 Berlex Lab N-heterocyclic derivatives as nos inhibitors
US5925639A (en) 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US6399612B1 (en) 1997-10-06 2002-06-04 Warner-Lambert Company Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
WO1999021583A1 (en) 1997-10-29 1999-05-06 Warner-Lambert Company Method of inhibiting metastases of cancer cells
EP1047450B1 (en) 1997-12-23 2002-10-02 Warner-Lambert Company Ace inhibitor-mmp inhibitor combinations
US6169103B1 (en) 1998-03-03 2001-01-02 Warner-Lambert Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
HUP0103714A3 (en) 1998-05-11 2003-05-28 Takeda Pharmaceutical Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity, medicaments containing them and their use
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
ATE254105T1 (de) 1998-09-25 2003-11-15 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
JP4183350B2 (ja) 1998-10-28 2008-11-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 フェニルピロリジノン誘導体
US6541521B1 (en) 1999-07-12 2003-04-01 Warner-Lambert Company Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases
WO2001032608A1 (en) 1999-10-29 2001-05-10 Takeda Chemical Industries, Ltd. Process for the preparation of oxyiminoalkanoic acid derivatives
AU1303301A (en) 1999-11-10 2001-06-06 Takeda Chemical Industries Ltd. Body weight gain inhibitors
WO2001034579A1 (en) 1999-11-10 2001-05-17 Takeda Chemical Industries, Ltd. Alkoxyiminoalkanoic acid derivatives
GB0003671D0 (en) 2000-02-17 2000-04-05 Univ Cardiff Diphenyl-substituted lower alkanes
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
EP1340749A4 (en) 2000-11-17 2007-09-05 Takeda Pharmaceutical ISOXAZOLE DERIVATIVES
US20040077557A1 (en) 2000-12-21 2004-04-22 Sulejman Ali Macrolide antibiotics
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
JP2002241358A (ja) 2001-02-15 2002-08-28 Nippon Soda Co Ltd オキシム基を有する化合物及び殺虫・殺ダニ剤
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
WO2002098840A1 (en) 2001-06-04 2002-12-12 Eisai Co., Ltd. Carboxylic acid derivative and medicine comprising salt or ester of the same
AU2002314944B2 (en) 2001-06-08 2008-03-06 Cytokine Pharmasciences, Inc. Isoxazoline compounds having MIF antagonist activity
US6552188B2 (en) 2001-06-29 2003-04-22 Kowa Co., Ltd. Unsymmetrical cyclic diamine compound
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
JP4303109B2 (ja) 2001-10-04 2009-07-29 メルク エンド カムパニー インコーポレーテッド 代謝共役型グルタミン酸受容体−５のヘテロアリール置換テトラゾール調節剤
DE60223720T2 (de) 2001-12-18 2008-10-30 Merck & Co., Inc. Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
AU2003265398A1 (en) 2002-08-09 2004-02-25 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
WO2004026833A1 (ja) 2002-09-20 2004-04-01 Takeda Pharmaceutical Company Limited 環状アミン化合物、その製造法および用途
AU2003280558A1 (en) 2002-10-11 2004-05-04 Kowa Co., Ltd. Method for treatment of cancer
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
EP1565436B1 (en) 2002-11-27 2012-04-25 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
EP1581493A1 (en) 2002-12-30 2005-10-05 Eli Lilly And Company Factor xa inhibitors
WO2004080535A2 (en) * 2003-03-12 2004-09-23 Millennium Pharmaceuticals, Inc. Methods and compositions for treating aids and hiv-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982, or 46777
JP2006521357A (ja) 2003-03-24 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物
AU2003902860A0 (en) 2003-06-06 2003-06-26 Daicel Chemical Industries, Ltd Benzimidazole compounds
CN1566065A (zh) 2003-06-27 2005-01-19 中国医学科学院药物研究所 α位杂原子取代的γ芳基丁本酮酸衍生物及其制法和其药物组合物与用途
SE0301963D0 (sv) 2003-07-02 2003-07-02 Astrazeneca Ab New compounds
MXPA06001002A (es) 2003-07-25 2006-04-11 Amgen Inc Piridonas y pirimidinonas sustituidas con propiedades antiinflamatorias.
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
GB0323581D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Novel compounds
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
JP2007509985A (ja) 2003-10-31 2007-04-19 ニューロジェン・コーポレーション カプサイシン受容体作動薬
CA2555402A1 (en) 2004-02-12 2005-09-01 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
US20050250826A1 (en) 2004-03-26 2005-11-10 Thais Sielecki-Dzurdz Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
ES2364340T3 (es) 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
CA2571361C (en) 2004-06-28 2011-07-26 F. Hoffmann-La Roche Ag Pyrimidine derivatives as 11beta-hsd1 inhibitors
JP2008510766A (ja) 2004-08-27 2008-04-10 ゲーペーツェー ビオテック アーゲー ピリミジン誘導体
JP4894517B2 (ja) 2004-08-27 2012-03-14 アステラス製薬株式会社 ２−フェニルピリジン誘導体
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
MX2007006790A (es) 2004-12-07 2007-08-15 Toyama Chemical Co Ltd Novedosos derivado de acido antranilico o sal del mismo.
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
WO2006133333A2 (en) 2005-06-07 2006-12-14 The Rockefeller University Stimulation of pancreatic b cell proliferation
DK1910384T3 (da) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
US20070060573A1 (en) 2005-08-10 2007-03-15 Lars Wortmann Acyltryptophanols
CA2618888A1 (en) 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
BRPI0615133A2 (pt) 2005-08-23 2011-05-03 Irm Llc compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso
TW200745055A (en) 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
CA2630233A1 (en) 2005-12-05 2007-06-14 Boehringer Ingelheim International Gmbh Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors
EP1966141A1 (en) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2007087637A2 (en) 2006-01-26 2007-08-02 Washington State University Research Foundation Compositions and methods using matrix metalloproteinase (mmp) inhibitors for treating cognitive impairment characterized by persistent or sustained mmp expression and/or activity
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
ES2303758B1 (es) 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
ATE555810T1 (de) 2006-02-24 2012-05-15 Astellas Pharma Inc Mittel zur behandlung oder prävention von verdauungsgeschwüren
JP2007230963A (ja) 2006-03-03 2007-09-13 Daiso Co Ltd ２，４−ジ置換ピリジンの製造法
PL3357911T3 (pl) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
GB0614579D0 (en) * 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
WO2008017691A1 (en) 2006-08-10 2008-02-14 Glaxo Group Limited Pyridine derivatives as sodium channel blockers
DK2054397T3 (en) 2006-08-16 2016-01-18 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
EP2054056A4 (en) 2006-08-16 2010-08-25 J David Gladstone Inst A Testa SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
TWI386405B (zh) 2006-09-05 2013-02-21 咪唑衍生物
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20080077419A1 (en) 2006-09-27 2008-03-27 Santiago Pamela M System And Method For Training Employees Of An Organization To Align Their Job Activities To Achieving The Organization's Strategic Objectives
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
WO2008045905A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
WO2008095852A1 (en) 2007-02-08 2008-08-14 Respiratorius Ab Bronchorelaxing arylamides
MX2009008935A (es) * 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
US20100101643A1 (en) 2007-03-29 2010-04-29 Sumitomo Chemical Company, Limited Compound, photoelectric converter and photoelectrochemical cell
EP2142498A2 (en) 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
EP2002834A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
PE20091309A1 (es) 2007-12-21 2009-09-30 Astrazeneca Ab Derivados de ciclohexilo como inhibidores de acetil coenzima a carboxilasa
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
CA2722159C (en) * 2008-04-24 2016-04-05 Newlink Genetics Corporation Substituted phenylimidazole compounds and their use as ido inhibitors
JP2009280521A (ja) 2008-05-22 2009-12-03 Daiso Co Ltd ２，４−ジ置換ピリジンの製造法
JP2011184298A (ja) 2008-06-02 2011-09-22 Sanwa Kagaku Kenkyusho Co Ltd 新規化合物及びその医薬用途
JP5465720B2 (ja) * 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
CA2730116A1 (en) 2008-07-08 2010-01-14 Boehringer Ingelheim International Gmbh Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors
WO2010011302A1 (en) 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ES2433423T3 (es) 2008-07-25 2013-12-11 H. Lundbeck A/S Derivados de adamantil diamida y usos de los mismos
US8691824B2 (en) 2008-08-04 2014-04-08 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP5693452B2 (ja) 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CA2739058A1 (en) 2008-10-15 2010-04-22 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative and use thereof for medical purposes
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
WO2010052448A2 (en) 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
JP2012508717A (ja) 2008-11-13 2012-04-12 バイエル・クロップサイエンス・アーゲー 殺真菌剤としての置換（ピリジル）−アジニルアミン誘導体
PE20120008A1 (es) 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
SG174463A1 (en) 2009-04-07 2011-10-28 Astrazeneca Ab Isoxazol-3(2h)-one analogs as therapeutic agents
CA2759083A1 (en) 2009-04-30 2010-11-04 Novartis Ag Imidazole derivatives and their use as modulators of cyclin dependent kinases
US20120041009A1 (en) 2009-05-18 2012-02-16 Sumitomo Chemical Company, Limited Pyrimidine compound and its use in pest control
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
TWI423962B (zh) 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
WO2011050323A1 (en) 2009-10-22 2011-04-28 The Washington University Compounds and methods for treating bacterial infections
US8946197B2 (en) 2009-11-16 2015-02-03 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
CA2787365A1 (en) 2010-01-25 2011-07-28 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
UA109650C2 (xx) 2010-02-27 2015-09-25 Біс-арилзв'язані арилтриазолони та їх застосування
TWI535442B (zh) * 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
NZ604831A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Apoptosis signal-regulating kinase inhibitors
AU2011303597A1 (en) 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
CA2819373A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
MX2014001088A (es) 2011-07-28 2015-03-19 Chdi Foundation Inc Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
KR20140072037A (ko) * 2011-08-30 2014-06-12 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
KR20150000882A (ko) 2012-04-05 2015-01-05 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노산소첨가효소 억제제들, 약학 조성물들 및 이의 사용 방법
EP3049077A4 (en) 2013-09-26 2017-02-15 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ES2754473T3 (es) 2013-09-26 2020-04-17 Chdi Foundation Inc Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas, y método de uso de los mismos

Also Published As

Publication number Publication date
SG11201700341PA (en) 2017-02-27
US10258621B2 (en) 2019-04-16
US20170209440A1 (en) 2017-07-27
CN106715421A (zh) 2017-05-24
IL250114B (en) 2019-06-30
CN114588157A (zh) 2022-06-07
WO2016011316A1 (en) 2016-01-21
CR20170061A (es) 2017-07-17
MX2017000779A (es) 2017-07-27
PE20170770A1 (es) 2017-07-04
KR20170026633A (ko) 2017-03-08
SV2017005357A (es) 2017-07-14
CA2955379C (en) 2022-12-13
AU2015289492B2 (en) 2020-02-20
CA2955379A1 (en) 2016-01-21
UA120856C2 (uk) 2020-02-25
EP3169684A1 (en) 2017-05-24
JP2017520610A (ja) 2017-07-27
IL250114A0 (en) 2017-03-30
PH12017500110A1 (en) 2017-05-29
AU2015289492A1 (en) 2017-02-02
ECSP17010817A (es) 2017-03-31
MX372995B (es) 2020-04-13
BR112017000922A2 (pt) 2018-01-16
EA201790147A1 (ru) 2017-07-31
EA034528B1 (ru) 2020-02-17
EP3169684A4 (en) 2018-02-21
CO2017001447A2 (es) 2017-07-19
ES2747633T3 (es) 2020-03-11
EP3169684B1 (en) 2019-06-26
AP2017009724A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2018001230A1 (es) Tratamiento de osteoartritis
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
CL2018000429A1 (es) Moduladores de la expresión de kras
BR112019007806A2 (pt) composição bucal de múltiplas fases para a liberação de agentes ativos para tratamento bucal
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2018001258A1 (es) Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX386598B (es) Compuestos antibacterianos.
CL2018001226A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
MX2016010071A (es) Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos.
MX376824B (es) 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj).
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
MX2016010051A (es) Composicion y metodo para ayudar a dormir.
MX2017004600A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201791182A1 (ru) Новые производные 2&#39;- и/или 5&#39;-аминокислотных эфиров фосфороамидатов 3&#39;-дезоксиаденозина в качестве противораковых соединений
MX2018003497A (es) Formulaciones de aminoacidos de liberacion modificada administradas por via oral.
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
MX2016012835A (es) Composiciones y metodos para tratar las espinillas.
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
EP4650000A3 (en) High concentration formulation
CL2017000118A1 (es) Métodos y composiciones para tratar desórdenes relacionados con el vih